Drug intelligence / Profile preview

IMGX-103

Development stage: Preclinical
Lead developer: IMGENEX
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IMGX-103 is a monoclonal antibody being developed by IMGENEX for the treatment of psoriasis. It is designed to target and neutralize interleukin-17A (IL-17A), a key pro-inflammatory cytokine involved in the pathogenesis of autoimmune and inflammatory diseases. By inhibiting IL-17A, IMGX-103 aims to reduce downstream inflammatory signaling and alleviate the symptoms of psoriasis. The drug is currently in the preclinical stage of development.

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on IMGX-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMGX-103.

Explore the full profile